Universal Registration Document

Overview

The report describes Adocia's continued development of diabetes and obesity therapies in 2024, including the completion of final dosing in the BioChaperone Lispro Phase 3 program in China. It also highlights promising preclinical results from the AdOral peptide-delivery platform and ongoing work on AdoGel and AdoShell. The company reported 77 employees at year-end, alongside detailed social, safety, waste, water, and electricity disclosures.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Publication date: 29 April 2025
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services